IL23R and inflammatory bowel disease: The drug PTG-200, acting as an antagonist of IL23R has just passed Phase I and is in Phase II trials for IBD treatment (Cheng et al., 2019), which aligns well with the genetic/MR evidence implemented in EpiGraphDB.